Trial Profile
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS IN ADULT SUBJECTS WITH TYPE 1 DIABETES MELLITUS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2023
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms GLITTER 1
- Sponsors Gan&Lee Pharmaceuticals
- 13 Oct 2023 According to a Gan&Lee Pharmaceuticals media release, data from this study were presented at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting.
- 13 Oct 2023 Results presented in a Gan&Lee Pharmaceuticals media release.
- 06 Oct 2023 Primary endpoint has been met, (Immunogenicity), Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes